Barclays Increases Stake in Neurocrine Biosciences

Institutional investor boosts holdings in biotech firm by 12% in third quarter

Mar. 10, 2026 at 7:20am

Got story updates? Submit your updates here. ›

Barclays PLC has increased its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 12% in the third quarter, according to a recent filing with the Securities and Exchange Commission. The institutional investor now owns 303,978 shares of the biopharmaceutical company's stock, valued at $42.6 million.

Why it matters

Neurocrine Biosciences is a prominent biotech firm focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. The increase in Barclays' stake suggests the investment firm sees growth potential in the company's pipeline and commercial products.

The details

Barclays acquired an additional 32,588 shares of Neurocrine Biosciences in the third quarter, bringing its total ownership to about 0.3% of the company's outstanding stock. Several other institutional investors also increased their positions in Neurocrine during the quarter, including Arrowstreet Capital, Capital Fund Management, and Rhenman & Partners Asset Management.

  • Barclays increased its stake in Neurocrine Biosciences during the third quarter of 2026.

The players

Barclays PLC

A multinational investment bank and financial services company headquartered in London, England.

Neurocrine Biosciences, Inc.

A biopharmaceutical company focused on developing treatments for neurological, endocrine and neuropsychiatric disorders, headquartered in San Diego, California.

Got photos? Submit your photos here. ›

The takeaway

Barclays' increased stake in Neurocrine Biosciences suggests the investment firm sees strong growth potential in the biotech company's product pipeline and commercial operations, which could signal positive momentum for the stock going forward.